Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+74.5%
5Y CAGR+126.7%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+74.5%/yr
vs +217.6%/yr prior
5Y CAGR
+126.7%/yr
Recent deceleration
Acceleration
-143.1pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
59.9x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $143.35M | +109.0% |
| 2024 | $68.60M | +58.6% |
| 2023 | $43.27M | +60.4% |
| 2022 | $26.97M | +89.7% |
| 2021 | $14.22M | +494.4% |
| 2020 | $2.39M | - |
| 2019 | $0.00 | -100.0% |
| 2018 | $265000.00 | +2.7% |
| 2017 | $258000.00 | +2.4% |
| 2016 | $252000.00 | - |